Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elixir Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Lenny Guarente, PhD, in a molecular genetics laboratory at the Massachusetts Institute of Technology, has found single gene mutations that appear to double the life span of single-celled yeast. Cynthia Kenyon, PhD, a biochemist with the University of California, has found a similar gene that appears to contribute to long life in roundworms. Elixir Pharmaceuticals Inc. was founded to apply the research of Guarente and Kenyon to that higher-order, two-legged mammal known as man.

You may also be interested in...



Mining the Mitochondria for Clues to Cell Survival Mechanisms

Researchers have identified a protein in the mitochondria -- where cells generate the energy needed to drive biological processes -- that is dramatically upregulated by nutrient restriction. It appears to protect the cell from stress, in keeping with observations that caloric restriction diets slow aging. The researchers go on to show that a set of other proteins activated in turn by this process may be targets for the development of therapies for neurodegenerative diseases and diabetes.

Mining the Mitochondria for Clues to Cell Survival Mechanisms

Researchers have identified a protein in the mitochondria -- where cells generate the energy needed to drive biological processes -- that is dramatically upregulated by nutrient restriction. It appears to protect the cell from stress, in keeping with observations that caloric restriction diets slow aging. The researchers go on to show that a set of other proteins activated in turn by this process may be targets for the development of therapies for neurodegenerative diseases and diabetes.

Profiles of Two Iconoclasts

In recent years, most venture capital firms have focused on investing in companies with well-developed product pipelines. In this issue of START-UP, we profile two trendsetters: Fred Cohen, managing director at Texas Pacific Group Ventures; and Christoph Westphal, formerly a partner at Polaris Ventures and now vice chairman and CEO of Sirtris Pharmaceuticals. Both men are physician scientists turned investors, who have tapped into their scientific and clinical knowledge to make investments in "high concept" discovery stage companies. And although the investments are intriguing, it's too early to say whether or not the strategies adopted by these two men will yield returns for their backers.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel